<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="letter"><?properties open_access?><!-- Original-type: sc--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11286464</article-id><article-id pub-id-type="pmc">2363834</article-id><article-id pub-id-type="pii">6691472</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1472</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Neri</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cini</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Andreoli</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Boffi</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Francesconi</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mazzanti</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Medi</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mercatelli</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Romano</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Siliani</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tarquini</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Moretti</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Internal Medicine and Oncological Day Hospital, University of Florence, Italy</aff><aff id="aff2"><label>2</label>Department of General Pathology and Experimental Oncology, University of Florence, Italy</aff><aff id="aff3"><label>3</label>Institute of General Surgery, University of Florence, Italy</aff><aff id="aff4"><label>4</label>Department of Surgery, Careggi Hospital, Florence, Italy</aff><aff id="aff5"><label>5</label>Department of Surgery, Civic Hospital, Viareggio, Italy</aff><aff id="aff6"><label>6</label>Department of Clinical Physiopathology, University of Florence, Italy</aff><pub-date pub-type="ppub"><month>04</month><year>2001</year></pub-date><volume>84</volume><issue>7</issue><fpage>878</fpage><lpage>880</lpage><history><date date-type="received"><day>06</day><month>04</month><year>2000</year></date><date date-type="rev-recd"><day>31</day><month>07</month><year>2000</year></date><date date-type="accepted"><day>09</day><month>08</month><year>2000</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Adjuvant chemotherapy of gastric cancer after curative resection is still subject to discussion. In this study 137 patients with gastric adenocarcinoma, all with positive nodes, were randomized after curative resection so that 69 received epidoxorubicin (EPI), leucovorin (LV) and 5-fluorouracil (5-FU) on days 1&#x02013;3 every 3 weeks for 7 months, whereas the remaining 68 did not. After a follow-up period of 5 years, 21 of the 69 treated patients (30&#x00025;) and nine controls (13&#x00025;) were still alive; median survival time was 18 months for the controls and 31 months for the patients treated with adjuvant chemotherapy (<italic>P</italic>&#x0003c; 0.01). &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>adjuvant chemotherapy</kwd><kwd>epidoxorubicin</kwd><kwd>5-fluorouracil</kwd><kwd>gastric cancer</kwd><kwd>leucovorin</kwd><kwd>randomized trial</kwd></kwd-group></article-meta></front></article>


